• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Ad26.RSV.preF-RSV vaccination prevents RSV infection in older adults

byBryant LimandKiera Liblik
February 24, 2023
in Infectious Disease, Public Health, Pulmonology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this randomized controlled trial, vaccination with Ad26.RSV.preF-RSV preF protein was associated with significantly reduced respiratory syncytial virus (RSV) infection in older adults compared to placebo.

2. While solicited local and systemic adverse events were higher in the vaccine group than in the placebo group, the frequency of serious adverse events was similar between the two groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: RSV is a leading cause of lower respiratory tract disease in older adults, with potentially severe complications such as pneumonia and the exacerbation of underlying conditions. There are currently no approved RSV vaccinations. In this phase two randomized controlled trial, the efficacy, immunogenicity, and safety of the Ad26.RSV.preF-RSV preF protein vaccine was evaluated for the prevention of RSV infection in adults over the age of 65. Participants were randomly assigned to receive either one intramuscular vaccine or saline placebo injection and followed for six months or until the end of the RSV season. The incidence of RSV-mediated lower respiratory tract infection was significantly lower in the vaccine group compared to the placebo group. For immunogenicity, titers of neutralizing antibodies against RSV A and RSV B, levels of serum RSV preF IgG antibodies, and RSV-F-specific interferon-Îł T-cell frequencies increased in the vaccine group at day 15 and remained above baseline for at least six months. For safety outcomes, the incidence of serious adverse events was not significantly different between groups. Solicited systemic adverse events were more common in the vaccine group compared to the placebo group. As a limitation, the trial was shortened due to the onset of the COVID-19 pandemic. Analysis was conducted on the per-protocol efficacy population, rather than the intention-to-treat protocol, which may bias results. There were also few participants older than 85, and the study was unable to evaluate the safety and efficacy of the RSV vaccine for this age population.

Click to read the study in NEJM

In-Depth [randomized controlled trial]: In this phase two randomized clinical trial, the efficacy and safety of the Ad26.RSV.preF-RSV preF protein vaccine was evaluated. Participants (n=5,782) aged 65 or over in stable health were randomly assigned in a 1:1 ratio to receive either one intramuscular injection of vaccine (n=2,891) or saline placebo (n=2,891). Participants were followed for six months or until the end of the RSV season. The primary outcome was the first occurrence of RSV-mediated lower respiratory tract disease according to one of three definitions: three or more symptoms of lower respiratory tract infection (definition one), two or more symptoms of lower respiratory tract infection (definition two), and either two or more symptoms of lower respiratory tract infection or one or more symptoms of lower respiratory tract infection plus at least one systemic symptom (definition three). For the primary outcome, the vaccine efficacy against illness meeting case definitions one, two, and three were 80% (94.2% Confidence Interval [CI], 52.2 to 92.9; p<0.001), 75% (94.2% CI, 50.1 to 88.5; p<0.001), and 69.8% (94.2% CI, 43.7 to 84.7; p<0.001), respectively. A subset of the study population was evaluated for immunogenicity (n=195). In the vaccine group, the geometric mean titer of RSV A2 and B neutralizing antibodies increased by a factor of over nine at day 15 compared to baseline and remained over four times the baseline value at day 169. The concentrations of serum preF IgG antibodies and RSV-F-specific T-cell frequency were also higher on days 15 and 169. No changes in immunogenicity measures were observed in the placebo group. The incidence of serious adverse events was not significantly different between groups. Solicited systemic adverse events were higher in the vaccine group (41.4%) compared to the placebo group (16.4%). In summary, Ad26.RSV.preF-RSV preF protein vaccine may be useful in reducing the incidence of RSV infection in older adults.

RELATED REPORTS

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

2 Minute Medicine Rewind June 9, 2025

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

Image: PD

©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Ad26.RSV.preF-RSV preF protein vaccineinfectious diseasepreventative medicinepublic healthpulmonologyrespiratory syncytial virus (RSV)respirologyRSVRSV vaccinevaccination
Previous Post

Screen time and sedentary lifestyle associated with increased obesity rates among adolescents

Next Post

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

RelatedReports

Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription
Infectious Disease

Trimethoprim-sulfamethoxazole during pregnancy does not reduce risk of prematurity

June 9, 2025
Weekly Rewinds

2 Minute Medicine Rewind June 9, 2025

June 9, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Cardiology

Sotatercept reduces adverse event risk in high-risk pulmonary arterial hypertension

June 5, 2025
Government-funded initiatives provide important supports to low-income HIV patients
Infectious Disease

Second-line TAF-based ART improves viral suppression in pediatric HIV

June 4, 2025
Next Post
Mesenchymal precursor cell transplant did not improve weaning from device support in LVAD patients

Days alive out of hospital after ventricular assist device implantation vary with comorbidity status

#VisualAbstract: Treatment with ivermectin does not improve time to sustained recovery in outpatients with mild to moderate COVID-19

#VisualAbstract: Treatment with ivermectin does not improve time to sustained recovery in outpatients with mild to moderate COVID-19

Prescription of antibiotics for acute respiratory infections increasing

Antipsychotic medication analysis among older adults with infection-related delirium

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
  • Ablation may reduce stroke risk, death, heart failure hospitalization in patients with atrial fibrillation
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.